Compare IDEXX Laboratories, Inc. (IDXX) vs Microsoft (MSFT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Microsoft — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while Microsoft trades at $535.07 (market cap $3.88T). The key difference: Microsoft is far larger — about 96× IDEXX Laboratories, Inc.'s market cap, and Microsoft pays a 0.75% dividend while IDEXX Laboratories, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and Microsoft for 142 Days on average.
| IDXX | MSFT | |
|---|---|---|
Market Cap | $40.43B | $3.88T |
Volume | 692,164 | 19,593,392 |
Sector | Health | Technology |
52-Week High | $766.68 | $542.07 |
52-Week Low | $504.70 | $352.83 |
Typical Hold Time | 46 Days | 142 Days |
Enterprise Value | $41.32B | $3.86T |
Dividend Yield | — | 0.75% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
Microsoft (MSFT) trades at $522.61, down 1.35% on the day, with strong technical support at $517 and resistance at $530. The company demonstrates robust fundamentals with 2025 revenue of $281.72B and net income of $101.83B, maintaining a 40.31% net margin. Recent earnings beats and bullish analyst consensus support the stock's long-term growth trajectory despite near-term volatility.
Outlook remains positive with 81.7% analyst buy ratings and $571.76 consensus price target, representing 9.4% upside. Key risks include increased capital expenditure concerns and competitive pressures in AI, but Microsoft's strong cloud positioning and consistent earnings growth provide solid foundation for investor confidence.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Microsoft
Microsoft Corporation develops, manufactures, licenses, sells, and supports software products. The Company offers operating system software, server application software, business and consumer applications software, software development tools, and Internet and intranet software. Microsoft also develops video game consoles and digital music entertainment devices.
Read more on MSFT →
